Android app on Google Play

Ironwood Pham (IRWD) and Forest Labs (FRX) Announces Presentation Plans for Linaclotide Results from Phase 2B and Phase 3 Trials

October 27, 2011 8:39 AM EDT Send to a Friend
Get Alerts IRWD Hot Sheet
Trade IRWD Now!
Join SI Premium – FREE
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced they will be presenting additional linaclotide results from four pivotal Phase 3 trials and one Phase 2b study in patients with either irritable bowel syndrome with constipation or chronic constipation at the American College of Gastroenterology 2011 Annual Scientific Meeting being held in Washington, DC from October 29, 2011 to November 2, 2011.

Linaclotide is an investigational guanylate cyclase type-C agonist for the treatment of IBS-C and chronic constipation Positive results from each of these trials have been reported previously.

The linaclotide results will be presented in three poster presentations:
  • Poster P765 describes a pooled analysis from the two pivotal Phase 3 IBS-C trials. This poster is authored by Dr. William D. Chey and will be presented on Monday, October 31 from 10:30 a.m. – 4:30 p.m. (Eastern Time).
  • Poster P764 describes a pooled analysis of patients with at least moderate bloating from the two pivotal Phase 3 CC trials. This poster is authored by Dr. Anthony Lembo and will be presented on Monday, October 31 from 10:30 a.m. – 4:30 p.m. (Eastern Time).
  • Poster P1170 provides an assessment of endpoints used in evaluating treatments for IBS-C and is based on the Phase 2b IBS-C clinical study of linaclotide. This poster is authored by Dr. Jeff Johnston and will be presented on Tuesday, November 1 from 10:30 a.m. – 4:30 p.m. (Eastern Time).





You May Also Be Interested In


Related Categories

Corporate News, FDA

Add Your Comment